Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Checkpoint Therapeutics stock

Learn how to easily invest in Checkpoint Therapeutics stock.

Checkpoint Therapeutics Inc is a biotechnology business based in the US. Checkpoint Therapeutics shares (CKPT) are listed on the NASDAQ and all prices are listed in US Dollars. Checkpoint Therapeutics employs 10 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Checkpoint Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CKPT – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Checkpoint Therapeutics stock price (NASDAQ: CKPT)

Use our graph to track the performance of CKPT stocks over time.

Checkpoint Therapeutics shares at a glance

Information last updated 2022-01-16.
Latest market close$2.45
52-week range$2.22 - $5.38
50-day moving average $3.21
200-day moving average $3.01
Wall St. target price$15.80
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.52

Buy Checkpoint Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in most equities.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$10 of crypto
Open an account with access to crypto
A platform built for all kinds of traders and all styles of trading
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stash Invest
Stocks, ETFs
$1 per month
Add at least $5 to your Invest account
Stash is more than an investment app. You’ll have access to tools that can help you become a confident investor.
Stocks, ETFs, Cryptocurrency
$0 per month
Download and sign up with; approved accounts receive a free stock slice worth up to $300, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
Stocks, Options, ETFs
$0 per year
Get a free stock valued up to $3500
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Checkpoint Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Checkpoint Therapeutics price performance over time

Historical closes compared with the close of $2.45 from 2022-01-18

1 week (2022-01-09) N/A
1 month (2021-12-17) -16.67%
3 months (2021-10-18) -22.47%
6 months (2021-07-20) -12.19%
1 year (2021-01-20) -33.60%
2 years (2020-01-17) 35.36%
3 years (2019-01-18) 3.6
5 years (2017-01-20) 11

Checkpoint Therapeutics financials

Revenue TTM $279,000
Gross profit TTM $-15,283,000
Return on assets TTM -44.87%
Return on equity TTM -88.22%
Profit margin 0%
Book value $0.58
Market capitalisation $218.6 million

TTM: trailing 12 months

Checkpoint Therapeutics share dividends

We're not expecting Checkpoint Therapeutics to pay a dividend over the next 12 months.

Checkpoint Therapeutics share price volatility

Over the last 12 months, Checkpoint Therapeutics's shares have ranged in value from as little as $2.22 up to $5.376. A popular way to gauge a stock's volatility is its "beta".

CKPT.US volatility(beta: 1.6)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Checkpoint Therapeutics's is 1.6031. This would suggest that Checkpoint Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Checkpoint Therapeutics overview

Checkpoint Therapeutics, Inc. , a clinical-stage immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7. 1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing CK-101, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Checkpoint Therapeutics, Inc. has collaboration agreements with TG Therapeutics, Inc.

Frequently asked questions

What percentage of Checkpoint Therapeutics is owned by insiders or institutions?
Currently 15.664% of Checkpoint Therapeutics shares are held by insiders and 14.02% by institutions.
How many people work for Checkpoint Therapeutics?
Latest data suggests 10 work at Checkpoint Therapeutics.
When does the fiscal year end for Checkpoint Therapeutics?
Checkpoint Therapeutics's fiscal year ends in December.
Where is Checkpoint Therapeutics based?
Checkpoint Therapeutics's address is: 2 Gansevoort Street, New York, NY, United States, 10014
What is Checkpoint Therapeutics's ISIN number?
Checkpoint Therapeutics's international securities identification number is: US1628281073
What is Checkpoint Therapeutics's CUSIP number?
Checkpoint Therapeutics's Committee on Uniform Securities Identification Procedures number is: 162828107

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site